{
    "Clinical Trial ID": "NCT00410813",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Dasatinib, 100 mg, Daily",
        "  Dasatinib, 100 mg PO daily until progression of disease",
        "INTERVENTION 2: ",
        "  Dasatinib, 70 mg, Twice Daily",
        "  Dasatinib, 70 mg PO twice daily until progression of disease"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Diagnosis of breast carcinoma meeting the following criteria:",
        "  Stage IV disease",
        "  Bone metastasis-predominant disease, defined as the presence of  1 bone metastasis with or without nonbone (visceral or soft tissue) disease where the number of bone metastases is at least the number of measurable visceral target lesions",
        "  Visceral disease that does not cause a reduction in ECOG performance status allowed",
        "  Must meet 1 of the following criteria:",
        "  Measurable disease within the past 28 days",
        "  Nonmeasurable disease with rising serum CA 15-3, CA 27-29, CEA, or CA-125 documented by 2 consecutive measurements taken  14 days apart with the most recent measurement being within the past 42 days",
        "  These measurements need not be consecutive, and the prior measurement could have been months to years prior to the current measurement if the marker is considered by the investigator to reflect disease progression",
        "  The second serum marker value must be greater than the institution's upper limit of normal and show  a 20% increase over the first measurement",
        "  No symptomatic brain or CNS metastases",
        "  Prior CNS or brain metastasis allowed provided it was treated with radiotherapy  8 weeks ago",
        "  No pleural or pericardial effusion",
        "  Hormone receptor status known",
        "  Estrogen receptor- and/or progesterone receptor-positive disease must have progressed on  1 hormonal therapy in the metastatic setting",
        "  PATIENT CHARACTERISTICS:",
        "  Male or female",
        "  Menopausal status not specified",
        "  Zubrod performance status 0-2",
        "  QTc < 450 msec by EKG",
        "  Ejection fraction  50% by MUGA or 2-dimensional echocardiogram with no significant abnormalities within the past 12 weeks for patients on trastuzumab",
        "  No active infection requiring systemic therapy",
        "  No uncontrolled concurrent condition that would preclude the ability to take oral medication, including the following:",
        "  Nausea",
        "  Vomiting",
        "  Diarrhea",
        "  Lack of physical integrity of the upper gastrointestinal tract",
        "  Malabsorption syndrome",
        "  No clinically significant cardiac disease, including the following:",
        "  Congestive heart failure",
        "  Symptomatic coronary artery disease",
        "  Cardiac arrhythmias not well controlled",
        "  Myocardial infarction within the past 12 months",
        "  No concurrent active malignancy",
        "  Prior malignancies allowed provided the patient is currently disease-free",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception during and for 3 months after completion of study therapy",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  No prior RankL inhibitor therapy",
        "  No more than 1 prior cytotoxic chemotherapy for metastatic disease",
        "  At least 3 weeks since prior chemotherapy and recovered",
        "  At least 1 week since prior radiotherapy to non-CNS disease and recovered",
        "  At least 3 weeks since prior and no concurrent intravenous bisphosphates (e.g., zoledronate)",
        "  At least 7 days since prior and no concurrent antiplatelet agents, including any of the following*:",
        "  Anticoagulants (e.g., tirofiban, eptifibatide, ticlopidine)",
        "  Aspirin or aspirin-containing combinations",
        "  Dipyridamole",
        "  Epoprostenol",
        "  Clopidogrel",
        "  Cilostazol",
        "  Abciximab NOTE: *Nonsteroidal anti-inflammatory drugs and medically indicated platelet-inhibiting medication allowed",
        "  At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:",
        "  HIV protease inhibitors (e.g., amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir)",
        "  Select antibiotics (e.g., ciprofloxacin, clarithromycin, doxycycline, enoxacin, isoniazid, telithromycin)",
        "  Azole antifungals (e.g., itraconazole, ketoconazole, miconazole, voriconazole)",
        "  Select anesthetics (e.g., ketamine, propofol)",
        "  Hypericum perforatum (St. John's wort)",
        "  Nefazodone",
        "  Nicardipine",
        "  Diclofenac",
        "  Quinidine",
        "  Imatinib mesylate",
        "  At least 7 days since prior and no concurrent medications that prolong the QTc interval, including any of the following:",
        "  Antiarrhythmic agents (e.g., quinidine, procainamide, disopyramide phosphate, amiodarone, sotalol hydrochloride, ibutilide, dofetilide)",
        "  Antipsychotic agents (e.g., chlorpromazine, mesoridazine, thioridazine, pimozide, haloperidol, droperidol)",
        "  Select antibiotics (e.g., erythromycin, clarithromycin, sparfloxacin, pentamidine)",
        "  Narcotic analgesics (e.g., levomethadyl, methadone, domperidone)",
        "  Calcium channel blockers (e.g., bepridil, lidoflazine)",
        "  Antimalarial agents (e.g., halofantrine, chloroquine)",
        "  Parasympathomimetic agents (e.g., cisapride)",
        "  Arsenic trioxide",
        "  No other concurrent antineoplastic therapy for breast cancer, including any of the following:",
        "  Radiotherapy",
        "  Chemotherapy",
        "  Immunotherapy",
        "  Biologic therapy",
        "  Hormonal therapy",
        "  Gene therapy",
        "  No concurrent grapefruit juice consumption",
        "  No concurrent short-acting antacid agents within 2 hours of dasatinib administration",
        "  Concurrent trastuzumab (Herceptin\u00ae) therapy for HER-2 positive patients allowed provided patients have been on continuous trastuzumab for  12 weeks"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-free Survival",
        "  RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed, unequivocal progression of non-measurable disease, the appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration, development of one or more new bone lesions from baseline, or symptomatic deterioration related to disease progression. Time from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at last date of contact.",
        "  Time frame: Up to 2 years",
        "Results 1: ",
        "  Arm/Group Title: Dasatinib, 100 mg, Daily",
        "  Arm/Group Description: Dasatinib, 100 mg PO daily until progression of disease",
        "  Overall Number of Participants Analyzed: 41",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: weeks  10.3        (8.4 to 16.7)",
        "Results 2: ",
        "  Arm/Group Title: Dasatinib, 70 mg, Twice Daily",
        "  Arm/Group Description: Dasatinib, 70 mg PO twice daily until progression of disease",
        "  Overall Number of Participants Analyzed: 38",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: weeks  15.3        (8.7 to 20.1)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/41 (14.63%)",
        "  Left ventricular systolic dysfunction 0/41 (0.00%)",
        "  Constipation 0/41 (0.00%)",
        "  Death not associated with CTCAE term - Death NOS 0/41 (0.00%)",
        "  Sudden death 0/41 (0.00%)",
        "  Inf w/normal ANC or Gr 1-2 neutrophils - Skin 0/41 (0.00%)",
        "  Inf w/normal ANC or Gr 1-2 neutrophils - UTI 1/41 (2.44%)",
        "  Rash: dermatitis associated w/Chemoradiation 0/41 (0.00%)",
        "Adverse Events 2:",
        "  Total: 12/38 (31.58%)",
        "  Left ventricular systolic dysfunction 1/38 (2.63%)",
        "  Constipation 1/38 (2.63%)",
        "  Death not associated with CTCAE term - Death NOS 1/38 (2.63%)",
        "  Sudden death 1/38 (2.63%)",
        "  Inf w/normal ANC or Gr 1-2 neutrophils - Skin 1/38 (2.63%)",
        "  Inf w/normal ANC or Gr 1-2 neutrophils - UTI 1/38 (2.63%)",
        "  Rash: dermatitis associated w/Chemoradiation 1/38 (2.63%)"
    ]
}